Genzyme Ireland Limited (final product manufacturing (fill/finish), primary and secondary packaging, labeling, quality control and batch release)

The drug is intended for long-term enzyme replacement therapy in patients with Pompe disease (acid alpha-glucosidase deficiency).

Dosage form: powder for preparation of concentrate for infusion solution

ATC: A16AB22